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Summary Protein expression of the putative tumour-suppressor gene DCC on chromosome 18q was evaluated in a panel of 16 matched
colorectal cancer and normal colonic tissue samples together with DCCmRNA expression and allelic deletions (loss of heterozygosity, LOH).
Determined by a polymerase chain reaction (PCR)-LOH assay, 12 of the 16 (75%) cases were informative with LOH occurring in 2 of the 12
cases. For DCC mRNA, transcripts could be detected in all analysed normal tissues (eight out of eight) by RT-PCR, whereas 6 of the 15
tumours were negative. DCC protein expression, investigated by immunohistochemistry using the monoclonal antibody 15041 A directed
against the intracellular domain, was homogeneously positive in all normal tissue samples. In tumour tissues, no DCC protein was seen in 11
out of 16 samples (69%). Forthe DCC codon 201, we found a loss of a wild-type codon sequence caused by mutation or LOH in at least 8 out
of 15 cases (53%) compared with the corresponding normal tissue. DCC protein expression was undetectable in eight of the nine tumours
missing both wild-type codons. Only one of the five tumours with retained DCC protein expression had no detectable wild-type codon 201. In
addition, 9 out of 15 normal tissue specimens were mutated in codon 201. In two out of three cases with homozygous wild-type codons in
peripheral blood lymphocyte (PBL) DNA, mutations were already observed in the tumour adjacent normal colonic mucosa. We conclude that
DCC immunostaining should be introduced in the clinicopathological routine because of its strong correlation with the known prognostic
markers 18q LOH and mutation of codon 201.
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Genetic alterations in multistep colorectal tumorigenesis include
loss of heterozygosity (LOH) of the putative tumour-suppressing
DCC (deleted in colon carcinoma) gene on chromosome 18q21.1
(Vogelstein et al, 1989; Fearon et al, 1990; lacopetta et al, 1994).
Although allelic deletions are infrequent in early or intermediate
stage adenomas, about 50% ofadvanced stage adenomas and more
than 70% of colorectal cancer (CRC) show LOH of chromosome
18q (Vogelstein et al, 1988). Recently, Jen et al (1995) have
reported that the status of chromosome 18q has prognostic value
for the clinical course and the survival of CRC patients giving
patients with stage II cancer and 18q LOH a similar prognosis than
patients with stage III cancer. Furthermore, 18q LOH correlates
with an increased likelihood ofdistant metastasis (Kern et al, 1989)
and is a strong predictive factor for deep muscle and lymphatic
invasion (lino et al, 1994). In more than 90% of carcinomas with
18q allelic loss the deleted region includes the DCC locus (Cho et
al, 1994). Reduced or missing mRNA expression was observed in
more than 50% ofCRC (Itoh et al, 1993) but a general mechanism
for inactivation ofthe remaining allele has not yet been elucidated.
The DCC gene encodes a neural cell adhesion-like trans-
membrane protein. Its extracellular region is composed of six
immunoglobulin-like domains and four fibronectin-type III
repeats. Functionally, the DCC gene product might control cell
division and it might play a critical role in embryonic development
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and cell differentiation (Edelman and Crossin, 1991; Chuong et al,
1994; Hedrick et al, 1994). As shown recently by Keino-Masu et
al (1996) in neural tissue, DCC is a netrin receptor that is required
for the guidance ofdeveloping axons. Outside the nervous system,
the DCC gene is also expressed in most epithelial tissues (Reale et
al, 1994). How its tumour-suppressive effect is achieved here is
still unclear. Probably, reduced or missing protein. expression
might contribute to poor differentiation or increased proliferation
or to metastasis through the loss ofadhesiveness.
The strong prognostic value of 18q LOH for clinical course and
survival ofpatients with CRC and the putative tumour-suppressive
function ofthe DCC gene product (Tanaka et al, 1991) asks for the
development ofa method directly detecting the DCCgene product
in CRC. As recently discovered by Hahn et al (1996), another
putative tumour-suppressor gene, the DPC4 gene (deleted in
pancreatic cancer locus 4), has been mapped to chromosome
18q21 very near to the DCC gene locus. Therefore, further
attempts on protein level are required to clarify if the DCC gene
itselfis causally involved in tumorigenesis as a tumour suppressor
(Thiagalingam et al, 1996). The aim of this study was to establish
an immunohistochemical assay for routine use and to correlate
these data with the results ofthe molecular genetic analysis.
MATERIALS AND METHODS
Tissue preparation and DNA/RNA extraction
Tissues were obtained from 16 CRC patients by surgical resection
and processed immediately after removal. After dissection of
588DCC geneproductin normal andmalignant colorectal tissues 589
Table 1 DCC LOH, status of codon 201, expression of DCC mRNA and protein in colorectal tissue samples
Patient Tumour LOH on Codon 201-Sall-patternd mRNA expressione Protein expression'
codea gradingb DCCgenec
Normal mucosa Tumour Normal mucosa Tumour Normal mucosa Tumour
LR Gl No loss + +/- NAg - ++
UZ Gl ui - - + + +/-
FB G2 No loss + + NA + + -
PD G2 ui + + NA + .-
TE G2 No loss +/- - NA NA +++-
IK G2 LOH +/- - + + +++-
HM G2 No loss +/- - NA + + -
MS G2 No loss +/- - + - +++-
CW G2 No loss + + NA + +/-
BG G3 No loss - - + + ++/- -
RM G3 No loss + + + + +
BN G3 No loss + + + + ++++-
AP G3 ui +/- - NA - ++ -
JS G3 LOH NA NA + - ++ -
KS G3 ui +/- - NA - ++ -
OT G3 No loss +/- - + - ++-
aPatient code is a random two-letter code. bGrading system described in 'Materials and methods'. CL, LOH; no loss (informative and no LOH detectable); ui,
(uniformative, homozygous band pattern in normal tissue). d+, -, +/- used as described in Figure 4.e+, DCC mRNA detection by RT-PCR and specific
hybridization verification as described in 'Materials and methods'; -, no detectable mRNA expression. '+, ++, +++ and - used as described in 'Materials and
methods'. +/- or ++/- reflect a mixed pattern of heterogenously stained tissue areas. sNA, not applicable.
tumour and normal mucosal tissue by macroscopical means and
with a security distance of at least 3 cm between the normal
sample and the tumour, the samples were split into three pieces
and quick frozen immediately for immunostaining and RNA and
DNA extractions. To prevent contamination with normal cells,
only tumour samples with less than 10% normal epithelial cells in
the cryosections were included in the present study. Normal
tissue samples with recognizable atypical cells were excluded.
Tumour grade was determined according to the World Health
Organization's classification. Genomic DNA was extracted with
the QIAamp Tissue Kit (Qiagen, Chatsworth, CA, USA). Total
cellular RNA was purified by a guanidinium thiocyanate-phenol-
chloroform single-step extraction procedure (Chomczynski and
Sacchi, 1987). DNA was also extracted from peripheral blood
lymphocytes (PBLs) from some patients.
LOH analysis by polymerase chain reaction (PCR)
generating a restriction fragment length polymorphism
(RFLP)
The PCR-RFLP-LOH assay was carried out as described previ-
ously (Huang et al, 1992). The primers used define a 396-bp
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Figure 1 DCC LOH analysis. RFLP can be seen after Mspl digestion as a
triple band pattern in normal tissue (lane N) with LOH in tumour tissue (lane
T) in cases IK and JS
intron 5. The primer sequences are LOH-U 5'-TGC ACC ATG
CTG AAG ATT GT-3' and LOH-D 5'-AGT AC ACA CAA GGT
ATG TG-3'. When the MspI restriction site is present, the gener-
ated 396-bp fragment will be cut into 257-bp and 139-bp fragments
afterMspI (Boehringer, Mannheim, Germany) digestion. The frag-
ments were separated on a 2.5% agarose gel. A triple band pattern
(396 bp, 257 bp and 139 bp) of normal tissue DNA is considered
'informative'. The lack ofthe large orthe two smaller fragments in
corresponding tumour tissue unmasks allelic loss (i.e. LOH).
Codon 201-mutation assay
The primers for the codon 201 mutation assay (Honsako et al,
1994) span a 155-bp fragment within exon 3 and the adjacent 3'
intron of the DCC gene. Only amplification of the wild-type
sequence with a CGA in codon 201 generates a diagnostic Sall
restriction site. A 200-ng sample of genomic DNA was used in a
reaction mixture (total 50 ,ul) containing each primer at 400 nM,
deoxynucleotide triphosphates at 200 ,UM and 4 units of Taq poly-
merase (Perkin-Elmer Cetus, Norwalk, CT, USA). Typical reac-
tion conditions included initial denaturation for 3 min at 95°C,
followed by 35 cycles of 1 min at 95°C, 1 min annealing at 65°C
and 2 min extension at 72°C and a final extension step for 10 min
at 72°C. The primer sequences were 201-U 5'-GTC TTG CCC
TCT GGA GCA TTG CAG ATC AGT-3' and 201-D 5'-CTG
AAG GCA ACA AAG AGC ATT GC-3'. After amplification,
PCR products were SalI (Boehringer, Mannheim) digested and
electrophoresed on a 8% polyacrylamide gel. DNA fragments
were visualized under UV light by staining with ethidium
bromide.
Reverse transcription-polymerase chain reaction
(RT-PCR) analysis and Southern blot analysis
For RT-PCR, 8 jig oftotal RNA were reverse transcribed into first-
strand complementary DNA (cDNA) with the antisense primer
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Figure 2 Southern blot analysis of a 233-bp DCC RT-PCR product (lane D)
using a specific oligonucleotide probe (see 'Materials and methods'), cases
BG and OT. In case OT a DCC-specific hybridization signal can not be
detected. 202 bp 1-actin control (lane Ac) amplification and hybridization with
a f-actin specific probe
DCC-D 5'-AGC CTC ATT TTC AGC CAC ACA-3' using 25
units of Moloney murine leukaemia virus (MMLV) reverse tran-
scriptase (Gibco BRL, Gaithersburg, MD, USA) in a 30-gI reac-
tion volume. A 6-gl sample of the cDNA reaction mixture were
directly used for PCR amplification using the conditions described
above but with a different annealing temperature of 550C. The
PCR amplification was carried out using the antisense primer
DCC-D and the sense primer DCC-U 5'-TTC CGC CAT GGT
TTT TAA ATC A-3' (Fearon et al, 1990) generating a 233-bp PCR
product (nucleotide 986 to 1218). The primers span an intron to
prevent undiscerned genomic amplification. After separation on a
2% agarose gel and transfer to a nylon membrane, hybridization
was performed with a 32P-labelled 57-mer-oligonucleotide span-
ning nucleotide 1141 to 1197 of the DCC cDNA or with a 32p_
labelled 233-bp cDNA reference fragment according to nucleotide
sequence 986 to 1218 as described by Fearon et al, (1990). Each
PCR procedure was performed simultaneously with the ,B-actin
primers Ac-U 5'-CCT TCC TGG GCA TGG AGT CCT-3' and Ac-
D 5'-GGA GCA ATG ATC TTG ATC TT-3' generating a 202-bp
fragment as control reaction. The P-actin 19-mer oligonucleotide
Ac-H 5'-GTG GAT GCC ACA GGA CTC C-3' hybridizing within
the 202-bp fragment was used as positive control in Southern blot
analysis (Ponte et al, 1984).
Immunohistochemical analysis
Intensity and tissue localization of DCC protein expression were
evaluated by immunohistochemistry. Cryosections (7 gm) from
matched tumour and normal mucosal tissues were prepared, fixed
for 20 min at 4°C in 1% paraformaldehyde and washed three
times with 0.01 M phosphate-buffered saline (PBS), pH 7.4.
Subsequently, they were incubated with purified murine anti-
human DCC monoclonal antibody 15041A (PharMingen, San
Diego, CA, USA), directed against the intracellular domain of the
DCC gene produce at 2 ,ug ml-' in PBS for 45 min at room temper-
ature in a humidified chamber. Positive and negative controls with
an identical isotype (IgGI) were carried out in the same way for
each tissue specimen. Incubation with the secondary horseradish
peroxidase conjugated and preabsorbed anti-mouse antibody P
260 (Dako, Hamburg, Germany) was performed at 20-fold dilution
in PBS including 35% immunoglobulin-free fetal calf serum for
45 min at room temperature. Specifically bound antibody was then
visualized as described previously (Dippold et al, 1985) by peroxi-
dase catalysed substrate conversion of 3-amino-9-ethylcarbazole
with 0.03% hydrogen peroxide and subsequent counterstaining
with haematoxylin. The intensity ofcellular staining was classified
as '+++' when more than 50% ofthe cells were stained positively;
'+', when less than 10% of the cells were stained positively; '++',
when staining reactivity was between 10 and 50% and '-' when no
staining was detectable in any cell.
RESULTS
In the present study, we compared 16 matched CRC and normal
colonic tissue samples with genetic alterations of the DCC gene
locus and DCC mRNA and protein expression.
LOH analysis
Allelic losses of the DCC gene were determined with a
PCR-RFLP-LOH assay generating a PCR product with a diag-
nostic MspI restriction pattern. A total of 12 ofthe 16 (75%) cases
were informative and LOH was detected in 2 out of 12 cases
(Table 1). A loss ofboth DCCalleles was not observed in any case.
Representative examples of diagnostic MspI restriction patterns
are displayed in Figure 1.
mRNA expression
To determine the level of DCC transcription, total RNA was
analysed by Northern blot. No hybridization signal was detectable
(data not shown). Therefore, poly(A)+-purified RNA from three
colon carcinoma cell lines was analysed and a weak hybridization
signal was observed in one of the three lines (data not shown). To
detect the unambiguously low copy DCC message, a RT-PCR
analysis was applied. In all analysed cases normal tissue was DCC
positive (eight out of eight). A total of 6 of the 15 (40%) tumours
showed no detectable DCC transcript. Although our data are in
good agreement with published data by Itoh et al (1993), we
cannot exclude that some DCC mRNA detected in the malignant
tissue specimens is due to contaminating normal colonic cells,
decreasing the percentage of DCC mRNA-negative tumours to
40%. In each case f-actin mRNA was analysed in parallel to
control the integrity ofthe mRNA population. Table 1 summarizes
the mRNA expression data and Figure 2 shows representative
examples of the RT-PCR analysis.
Protein expression
DCC protein expression was investigated by immunohistochem-
istry using the commercially available monoclonal antibody
15041A directed against the intracellular domain of the DCC
protein (Figure 3). All normal tissue specimens exhibited an
intense staining restricted to the mucosa. The most pronounced
DCC expression was found in the crypts, whereas staining of the
luminal surface was less intense and heterogeneous (Figure 3A).
Goblet cells, which account for approximately 20% of the crypt
epithelium, were always brightly positive. In tumour tissue no
DCC expression was seen in 11 out of 16 samples corresponding
to 69% of all cases (Figure 3D). When present in CRC, most
tumour tissues showed an inhomogeneous DCC distribution
pattern in these cases and DCC protein expression was higher in
well-differentiated carcinomas compared with moderately and
poorly differentiated ones. The inhomogeneous pattern in DCC
protein-expressing tumours may reflect the heterogeneity of
certain samples with focal alterations, explaining the presence of
focal immunoreactivity and a negative RT-PCR result obtained
from two adjacent tissue preparations of the same sample (patient
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Figure 3 Immunohistochemical analysis of DCC protein expression in normal colonic mucosa and colon carcinoma (x 200). Normal mucosa (A) and
corresponding carcinoma (B), case UZ; normal mucosa (C) and corresponding carcinoma (D), case PD
LR, Table 1). A summary of all immunohistochemical data is
listed in Table 1.
Codon 201 mutation analysis
It is believed that the retained DCC allele in patients suffering 18q
LOH is inactivated by localized mutations. Given the large size of
the DCC gene, only a few mutations have been identified so far
and none can account for the complete loss of the DCC protein in
the afflicted tissue (Cho and Fearon, 1995). The codon 201 assay
described by Honsako et al (1994) reveals the loss ofthe wild-type
sequence in codon 201 as result of a CGA (Arg) to GGA (Gly)
transition or as result of an allelic loss. In this assay, cleavage of a
generated PCR product by Sall is diagnostic and indicates the
presence of the wild-type codon 201. A triple band pattern
following Sall digestion is caused by the presence ofa mutant and
a wild-type codon 201. To exclude that a triple bandpattern results
from an incomplete restriction hydrolysis, every digestion process
was validated in parallel by a complete digestion of a wild-type
sample from colon carcinoma cell lines (data not shown). We
could show that the loss of the wild-type codon 201 is not
restricted to malignant tissue but also occurs with high frequency
in adjacent normal colorectal tissue. In our panel, 9 out of 15
normal tissue specimens were mutated in codon 201, two of them
in both DCC alleles. All nine corresponding CRCs exhibited an
alteration in both codons, indicating that any retained wild-type
codon was lost during malignant transformation. In one case, a
homozygous wild-type situation in the normal tissue shifted to a
heterozygous wild-type/mutant situation in the tumour. In five
cases, neither the normal nor the malignant tissue showed a loss of
Table 2 Presence of wild-type codon 201 and DCC protein expression in
colorectal tumours
Wild-type codon 201
DCC protein expression Presenta Absent
Detectable 4b 1b
Not detectable 2b 8b
aRetaining of at least one wild-type codon 201. bNumber of cases.
the wild-type codon 201. In summary, at least in 8 out of 15 cases
(53%) of the malignant tissues had acquired a new loss of wild-
type codon 201 compared with their corresponding normal
mucosa. Furthermore, DCC protein expression was missing in
eight of the nine tumours with loss in both wild-type codons, but
only one ofthe five tumours with retained DCC protein expression
had no detectable wild-type codon 201 (Table 2). Interestingly, in
all three cases in which PBL DNA was analysed (patients BG, AP
and LR), a homozygous wildtype situation was observed in the
PBLs, whereas in the corresponding normal colonic mucosa ofthe
CRC patients a loss of a wild-type codon had already occurred in
two cases (patients BG and AP). As described in 'Materials and
methods', a potential contamination ofthe normal mucosa sample
by tumour cells seems to be unlikely and can be excluded in the
case of patient BG with a homozygous wild-type codon 201
constellation in the PBL DNA but no detectable wild-type codon
201 in the tumour or in the adjacent normal mucosa. Therefore,
these findings indicate that the loss of the first wild-type codon
could be a premalignant alteration in the normal mucosa with a
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Figure 4 Codon 201 mutation assay, case AP. The 155-bp fragment (lane
ut, untreated) was digested with SalI and then electrophoresed. Detection of
an uncleaved 155-bp fragment and the two cleaved fragments (126 bp and
29 bp) is symbolized as '+/-', the appearance only of the 155-bp fragment as
- and the appearance only of the two smaller fragments as '+'. The last two
constellations contain no information about a potential allelic loss. Here, AP
shows '+/-' in carcinoma adjacent normal and '-' in tumour tissue. The wild-
type codon 201 has been lost by allelic deletion or codon 201 mutation; the
LOH assay for AP is uniformative. The examination of AP's PBL DNA (lane
PBL) with a complete cleavage of the 155-bp fragment ('+') could exclude a
codon 201 germline mutation, but implies a somatic codon 201 mutation in
one allele of the carcinoma adjacent normal colonic mucosa
sequential loss ofthe remaining wild-type codon in advanced CRC
tumorigenesis (Figure 4, Table 1).
DISCUSSION
The DCC gene on chromosome 18q is a candidate tumour-
suppressor gene that was previously characterized by systematic
evaluations of LOH in a series of CRC (Vogelstein et al, 1988,
1989; Fearon et al, 1990). Evidence for a tumour-suppressive
function of DCC arised from experiments by Klingelhutz et al
(1993), who have shown that it can suppress tumorigenesis when
exogenously introduced into neoplastic cells lacking DCC expres-
sion. In addition, the high prevalence of 18q LOH including the
DCC gene locus and its increasing frequency during colorectal
tumour development from early adenomatous stages to carcinoma
also argue for a tumour-suppressive function of the DCC gene
(Vogelstein et al, 1988).
The presence ofa functional protein in normal mucosa vs loss in
malignant tissue is a prerequisite for the putative tumour-suppres-
sive function of DCC. For a panel of gynaecological tumours
Enomoto et al (1995) reported reduced or lost expression in
endometrial and ovarian malignancies compared with the DCC
mRNA and protein expression levels in the corresponding normal
tissues. We examined DCC protein expression in a panel of
matched CRC and normal colonic mucosa. To prevent cross-reac-
tivity we used a monoclonal antibody against the non-homologous
intracellular region ofDCC that was not directed against the high
homologous extracellular immunoglobulin- or fibronectin-like
domains. As reported by Turley et al (1995), several murine mono-
clonal antibodies raised against extracellular epitopes of DCC
failed to detect the DCC protein in normal colonic epithelium.
According to the putative tumour-suppressive function ofthe DCC
gene produce and to former immunohistochemical results with a
polyclonal rabbit anti-DCC antibody raised against the intra-
cellular domain (Hedrick et al, 1994), an intense immunostaining
should be seen in normal colonic mucosa detected by a useful anti-
DCC antibody. With 15041A, we found that DCC protein expres-
sion is almost always lost in CRC, whereas the adjacent normal
mucosa is brightly positive, indicating that tumorigenesis is indeed
accompanied by the loss of DCC protein. In a few CRC cases,
DCC protein was still detectable, but DCC immunoreactivity was
mostly restricted to distinct areas. It will be ofinterest to determine
the DCC expression in primary and metastatic tumours in these
cases. Furthermore, the lower expression in only moderately or
poorly differentiated CRC supports the hypothesis that the loss
of DCC protein may account for the progression of colorectal
tumorigenesis.
The aim of this study was to establish a DCC expression assay
for routine clinical practice. Therefore, the tissue preparation
procedure had to be a simple macroscopical dissection. Although
we kept the contamination of our tumour specimens with normal
colonic mucosa cells as low as possible, the frequencies ofLOH or
lost mRNA expression detected by PCR may be underestimated.
We demonstrated LOH in 2 out of 12 informative cases, which is
not as frequent as usually reported for colorectal carcinoma,
although the published frequencies range widely from 20% to 70%
(Vogelstein et al, 1988; Sasaki et al, 1989). Compared with other
studies using only a few polymorphic markers or only one PCR
based LOH assay (Sasaki et al, 1989; lino et al, 1993; lacopetta et
al, 1994), our LOH frequency obtained from 16 matched tissue
samples after macroscopical dissection by PCR seems quite likely.
Even if we cannot exclude that some of the RT-PCR-positive
tumours would be DCC mRNA negative when tissue had been
prepared by time-consuming microdissection, our DCC mRNA
results are in good agreement with the literature (Itoh et al, 1993).
Presently, mainly 18q LOH is used in prognostic assessments. We
suggest that the measurement of DCC protein by immunohisto-
chemistry should be introduced in the clinicopathological routine
as an additional or alternative prognostic marker. It is easy to
perform, not influenced by adjacent normal tissue and only needs
small amounts ofmaterial.
Homozygous DCC gene deletions are restricted to a few
published cases (Fearon et al, 1990; Murty et al, 1994) and were not
seen in the present study. Typically, the inactivation of a tumour-
suppressor gene involves the allelic deletion of one of the two
parental alleles, detectable as LOH and according to Knudson
(1985) this unmasks a recessive mutation in the remaining allele. A
few somatically acquired point mutations in the DCC gene gener-
ating a novel splice acceptor site or nonsense or missense mutations
in the coding sequence as well as insertional mutagenesis in some
CRC cases have been reported (Fearon et al, 1990; Miyake et al,
1994). But without any evidence for a general molecular mecha-
nism leading to the inactivation of the DCC allele in CRC, the
analysis of additional mutations should be pursued. Therefore, we
analysed the loss of the wild-type codon 201 in CRC and adjacent
normal mucosa. Miyake et al (1994) had previously identified this
mutation as a 'polymorphic change' in a single case ofoesophageal
squamous cell carcinoma and its adjacent normal mucosa but
without any data about the codon 201 sequence in PBLs or other
somatic cells outside of the oesophageal mucosa. Our data indicate
that the C to G transition of the first base in codon 201 is indeed a
British Journal ofCancer(1998) 77(4), 588-594 0 Cancer Research Campaign 1998DCC geneproduct in normalandmalignant colorectal tissues 593
real mutation because all the three PBL samples analysed showed
completely digestible wild-type codons 201, whereas the pattern of
the Sall restriction hydrolysis was already different in two cases of
normal colorectal mucosa compared with the corresponding PBLs.
Honsako et al (1994) have found that the loss of wild-type codon
201 is significantly increased in invasive colorectal carcinomas and
carcinomas with distant metastasis. Thus, the epidemiological data
of 18q LOH (Kern et al, 1989; Iino et al, 1994) as well as the results
ofthe codon 201 study (Honsako et al, 1994) appear to be predictive
indicators for local invasion and distant metastasis in CRC. As
shown by Jen et al (1995) 18q LOH has strong prognostic value for
the outcome of CRC patients. To prove that DCC has a tumour-
suppressive function in colorectal tumorigenesis the prognostic
markers 18q LOH and loss ofwild-type codon 201 have to be asso-
ciated with reduced or absent expression of the DCC gene product
in CRC. In fact, we could show in the present study that the DCC
protein is not expressed in cases with proven LOH. In particular,
DCC immunoreactivity was negative in 89% (eight out of nine) of
the tumours with loss in both 201 wild-type codons whereas at least
one wild-type codon 201 was present in 80% (four out of five) of
the tumours with positive immunoreactivity (Table 2). We speculate
that loss ofboth wild-type codons 201 might interfere with the DCC
transcription or translation. Although our data suggest a correlation
between codon 201 and DCC protein expression, we do not believe
in loss of wild-type codon 201 as the only cause for inactivation of
the remaining allele. Therefore, a situation with no detectable wild-
type codon 201 does not lead inevitably to a loss of DCC protein
expression (patient UZ, Table 1). In addition, we found that the loss
of the wild-type codon 201 is not restricted to CRC. It also occurs
with high frequency in the adjacent normal mucosa, resulting in a
heterozygous allelotype with one wild-type and one mutant codon.
Upon malignant transformation, 53% ofthe tumours accumulate an
additional loss of the retained wild-type codon, thus exhibiting a
mutant phenotype with no wild-type codon 201. We speculate that
the loss ofthe first wild-type codon 201 could be an early premalig-
nant event in the colorectal adenoma-carcinoma-sequence. In a
further study, it will be of special interest to evaluate the codon 201
status in normal colonic mucosa without any evidence for adjacent
CRC and to analyse the biochemical importance of this missense
mutation in exon 3 related to the inactivation of a remaining DCC
allele.
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ADDENDUM
After submission of this manuscript, an immunohistochemical
study correlating the DCC protein expression and the prognosis in
colorectal cancer has been published (Shibata, D et al, 1996. N
Engl J Med 335: 1727-1732), confirming our thesis that immuno-
histochemical detection of the DCC protein expression might be a
useful clinicopathological marker.
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